Description

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C35H49N11O9S2—-[1]Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20.–188627-80-7–831.96–99.96–O=C(N(CCC1)[C@]1([H])C(N[C@@H](CSSCCC2=O)C(N)=O)=O)[C@](NC([C@@H](NC(CNC([C@@H](N2)CCCCNC(N)=N)=O)=O)CC(O)=O)=O)([H])CC3=CNC4=CC=CC=C34–Cardiovascular Disease–DMSO : 250 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)–Integrin—-Cytoskeleton–Peptides